ArticleCurrent pharmaceutical biotechnology2025

Clinical and Prognostic Implications of an Alternative Splicing-related Risk Model Based on TP53 Status in Breast Cancer.

Xinrui Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.